Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 259

1.

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70. Epub 2005 May 16.

2.

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.

Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.

3.

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H.

PLoS Med. 2005 Mar;2(3):e73. Epub 2005 Feb 22.

4.
5.

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.

Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M, Ono M.

Cancer Res. 2010 Nov 1;70(21):8715-25. doi: 10.1158/0008-5472.CAN-10-0043. Epub 2010 Oct 19.

6.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.

7.

Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.

Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.

Clin Cancer Res. 2014 Aug 1;20(15):4059-4074. doi: 10.1158/1078-0432.CCR-13-1559. Epub 2014 Jun 11. Erratum in: Clin Cancer Res. 2015 Aug 1;21(15):3571. Chen, Ann Y [corrected to Chen, Y Ann].

8.

Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.

Han SY, Zhao MB, Zhuang GB, Li PP.

Lung Cancer. 2012 Jan;75(1):30-7. doi: 10.1016/j.lungcan.2011.06.001. Epub 2011 Jul 16.

PMID:
21757251
9.

Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.

Moreira-Leite FF, Harrison LR, Mironov A, Roberts RA, Dive C.

J Thorac Oncol. 2010 Jun;5(6):765-77. doi: 10.1097/JTO.0b013e3181d95d93.

10.

Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.

Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A.

PLoS Med. 2007 Oct;4(10):1681-89; discussion 1690.

11.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
12.

JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.

Harada D, Takigawa N, Ochi N, Ninomiya T, Yasugi M, Kubo T, Takeda H, Ichihara E, Ohashi K, Takata S, Tanimoto M, Kiura K.

Cancer Sci. 2012 Oct;103(10):1795-802. doi: 10.1111/j.1349-7006.2012.02363.x. Epub 2012 Jul 24.

13.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
14.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, Truesdale AT, Shewchuk L, Wood ER.

Cancer Res. 2008 Jan 15;68(2):571-9. doi: 10.1158/0008-5472.CAN-07-2404.

15.
16.

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Jänne PA.

Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. doi: 10.1016/S0169-5002(08)70099-0. Review.

PMID:
18513582
17.

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA.

J Clin Invest. 2006 Oct;116(10):2695-706. Epub 2006 Aug 10.

18.

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T.

Clin Cancer Res. 2006 Oct 1;12(19):5764-9.

19.

Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.

Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.

Exp Cell Res. 2014 May 1;323(2):288-96. doi: 10.1016/j.yexcr.2014.02.026. Epub 2014 Mar 12.

PMID:
24631288
20.

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.

Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2008 Nov 15;14(22):7519-25. doi: 10.1158/1078-0432.CCR-08-0151.

Supplemental Content

Support Center